Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (26)

I-10Lars Lindbom

Addressing variability and uncertainty in pooled pre-clinical data improved the quality of compound selection of a gamma secretase modulator in Alzheimer’s Disease

Wednesday 10:15-11:45

I-16Arianna Madrid Aispuro

A Systematic Approach to PKPD Model Development to describe Sleep Effects of Compounds with Different Mechanisms of Action Using Semi-Mechanistic Markov Chain Models

Wednesday 10:15-11:45

I-21Amelie Marsot

Thiopental and esomeprazole in critically ill patients: Drug interaction.

Wednesday 10:15-11:45

I-49Klas Petersson

Simultaneous modeling of prolactin data following administration of seven D2–receptor antagonists in rats; Model-based in vitro – rat – human scaling

Wednesday 10:15-11:45

I-52Venkatesh Pilla Reddy

Translational PKPD modeling in schizophrenia: linking receptor occupancy of antipsychotics to efficacy and safety

Wednesday 10:15-11:45

I-54Bart Ploeger

Investigation of a Data Transformation Procedure to Improve Identifiability of Efficacy and Potency: Application to Continuous Elevated Plus-Maze Data in Rats

Wednesday 10:15-11:45

I-69Yu-Yuan Chiu

Dose-Response Model of Lurasidone Treatment in Schizophrenia

Wednesday 10:15-11:45

II-09Rik Schoemaker

Modelling and simulation of spontaneously reported adverse events after administration of lacosamide

Wednesday 15:10-16:40

II-12Kwang-Hee Shin

Population Pharmacokinetics and Pharmacodynamics of Escitalopram in Healthy Volunteers

Wednesday 15:10-16:40

II-18Nelleke Snelder

Quantification of Antidepressant and Sedative Effect of Two NMDA Channel Blockers, AZD6765 and Ketamine, in an Animal Model of Depression Using Count Data

Wednesday 15:10-16:40

II-30Stina Syvänen

P-glycoprotein alterations at the blood-brain barrier influences [11C]flumazenil brain concentrations but does not interfere with estimation of GABAA receptor density in a rodent model of epilepsy

Wednesday 15:10-16:40

II-46

Discrete distribution models for relapsing-remitting dynamics observed in Multiple Sclerosis

Wednesday 15:10-16:40

II-50Sandra Visser

MModel-based meta analysis of -secretase inhibitor data; has A production inhibition been adequately tested as therapeutic approach in mild AD?

Wednesday 15:10-16:40

II-53

Quantification of the Drug Effect and Exploration of Mechanism of Action of Two NMDA Channel Blockers, AZD6765 and Ketamine, using Mouse EEG Data

Wednesday 15:10-16:40

II-68Parviz Ghahramani

Population Pharmacokinetic Model for Cariprazine and its Major Metabolites in Patients with Acute Exacerbation of Schizophrenia

Wednesday 15:10-16:40

III-21Marcus Björnsson

A population PK/PD model for bispectral index of the fast acting anesthetic AZD3043 in healthy volunteers

Thursday 10:05-11:35

III-24Irina Bondareva

Population Pharmacokinetics of Phenytoin Estimated from Repeated Therapeutic Drug Monitoring (TDM) Data of Epileptic Patients

Thursday 10:05-11:35

III-63Farkad Ezzet

Power Calculation Based on Pharmacokinetic Sampling Designs of ELND005 in a Phase 3 Clinical Trial Design in Mild Alzheimer Disease Patients

Thursday 10:05-11:35

IV-16Sophie Glatt

A population pharmacokinetic analysis and pharmacokinetic/adverse events analysis of a sodium channel blocker in healthy subjects.

Thursday 15:00-16:30

IV-17

Title: Pharmacokinetic-Pharmacodynamic Modeling of the relationship between D2 receptor occupancy and Catalepsy in Rats: Predicting Extrapyramidal Side Effects in Humans

Thursday 15:00-16:30

IV-25Zheng Guan

Population PK/PD modeling to compare cannabinoid receptor antagonists in the THC challenge test

Thursday 15:00-16:30

IV-27Monia Guidi

Population Pharmacokinetics of Risperidone and 9-hydroxy-risperidone in psychiatric patients.

Thursday 15:00-16:30

IV-44Candice Jamois

Pharmacokinetic-Receptor Occupancy Modeling to support Phase 2 Dose Selection

Thursday 15:00-16:30

IV-46Juliette Janson

Population PKPD Modeling of BACE1 Inhibitor-Induced Reduction in Aβ Levels in vivo.

Thursday 15:00-16:30

IV-53Tatiana Karelina

Kinetic Model of Amyloid Beta Distribution and Allometric Scaling from Mouse to Monkey and Human

Thursday 15:00-16:30

IV-59

Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia

Thursday 15:00-16:30